Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Contineum Therapeutics In...

    NASDAQ: CTNM · Real-Time Price · USD
    3.92
    -0.37 (-8.62%)
    At close: Jun 17, 2025, 3:59 PM
    3.93
    0.38%
    After-hours: Jun 17, 2025, 04:04 PM EDT

    Contineum Therapeutics Class A Common Stock Statistics

    Share Statistics

    Contineum Therapeutics Class A Common Stock has 25.87M shares outstanding. The number of shares has increased by 0.58% in one year.

    Shares Outstanding

    n/a
    		 25.87M

    Shares Change (YoY)

    n/a
    		 0.58%

    Shares Change (QoQ)

    n/a
    		 0.36%

    Owned by Institutions (%)

    n/a
    		 80.91%

    Shares Floating

    n/a
    		 18.24M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,984

    FTD / Avg. Volume

    n/a
    		 2.08%

    Short Selling Information

    The latest short interest is 600.75K, so 2.32% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 600.75K

    Short % of Shares Out

    n/a
    		 2.32%

    Short % of Float

    n/a
    		 3.54%

    Short Ratio (days to cover)

    n/a
    		 5.26

    Valuation Ratios

    The PE ratio is -6.71 and the forward PE ratio is -1.48. Contineum Therapeutics Class A Common Stock's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -6.71

    Forward PE

    n/a
    		 -1.48

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 4.4

    PB Ratio

    n/a
    		 1.43

    P/FCF Ratio

    n/a
    		 -8.5

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Contineum Therapeutics Class A Common Stock.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 20.69, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 20.69

    Quick Ratio

    n/a
    		 20.69

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.15

    Debt / FCF

    n/a
    		 -0.19

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,030,682.93

    Employee Count

    n/a
    		 41

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -73.19% in the last 52 weeks. The beta is 0.51, so Contineum Therapeutics Class A Common Stock's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.51

    52-Week Price Change

    n/a
    		 -73.19%

    50-Day Moving Average

    n/a
    		 4.25

    200-Day Moving Average

    n/a
    		 11.08

    Relative Strength Index (RSI)

    n/a
    		 49.48

    Average Volume (20 Days)

    n/a
    		 95,580

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -50.89M

    Net Income

    n/a
    		 -42.26M

    EBITDA

    n/a
    		 -42M

    EBIT

    n/a
    		 -42.26M

    Earnings Per Share (EPS)

    n/a
    		 -2.18
    Full Income Statement

    Balance Sheet

    The company has 21.94M in cash and 6.26M in debt, giving a net cash position of 15.68M.

    Cash & Cash Equivalents

    n/a
    		 21.94M

    Total Debt

    n/a
    		 6.26M

    Net Cash

    n/a
    		 15.68M

    Retained Earnings

    n/a
    		 -117.4M

    Total Assets

    n/a
    		 198.26M

    Working Capital

    n/a
    		 183.19M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -32.84M and capital expenditures -514K, giving a free cash flow of -33.36M.

    Operating Cash Flow

    n/a
    		 -32.84M

    Capital Expenditures

    n/a
    		 -514K

    Free Cash Flow

    n/a
    		 -33.36M

    FCF Per Share

    n/a
    		 -1.72
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CTNM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CTNM is $21.5, which is 401.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $21.5

    Price Target Difference

    n/a
    		 401.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 3.21

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist